← Alle Unternehmen
Über das Unternehmen
Measuring the activity of genes in biological samples, such as blood, biopsies or stem cells, among others, has great medical potential for the discovery and development of new drugs and biomarkers. However, the discovery of new drugs and biomarkers normally requires the examination of large numbers (10000+) of samples from, for example, drug libraries and biobanks. This constitutes a severe challenge for existing RNA sequencing solutions, which can typically be applied only to small scale projects of maximum a few dozen samples. In order to fill this market and technological gap, we have developed a proprietary solution, called BRB-seq, which makes it possible for the first time to perform RNA sequencing in parallel on thousands of samples in a cost-efficient and high-throughput manner.